VivoSeq
Other

Hepatic Function

1

Pipeline Programs↗

3

Active Trials↗

31

Companies Involved↗

Hepatic Function is an early-stage landscape with 1 program across 31 companies. The most active players are Zealand Pharma, Novartis, Gilead.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Zealand Pharma logo

Zealand Pharma

1 program

Phase 1Novartis logo

Novartis

0 programs

PreclinicalGilead logo

Gilead

0 programs

PreclinicalA

Atea Pharmaceuticals, Inc.

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalRoche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Petrelintide

Zealand Pharma

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

61

clinical trials

Completed52 · 85%
Terminated4 · 7%
Recruiting2 · 3%
Withdrawn1 · 2%
Not yet recruiting1 · 2%
Unknown status1 · 2%

Clinical Trials

Trial Activity

61 trials

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Recruiting·AAtea Pharmaceuticals, Inc.·Phase 1·NCT06911320·28 enrolled
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Hepatic Function
Recruiting·Zealand Pharma logoZealand Pharma·Phase 1·NCT07682818·36 enrolled
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
Not yet recruiting·Sunshine Lake Pharma Co., Ltd. logoSunshine Lake Pharma Co., Ltd.·Phase 1·NCT05048368·32 enrolled
Pharmacokinetics Study in Patients With Impaired Hepatic Function
Completed·Astellas logoAstellas·Phase 1·NCT02586194·24 enrolled
A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function
Completed·Roche logoRoche·Phase 1·NCT04226833·38 enrolled
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 1·NCT01887301·32 enrolled
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
Completed·Novartis logoNovartis·Phase 1·NCT01443481·38 enrolled
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Completed·Novartis logoNovartis·Phase 1·NCT02474537·31 enrolled
Evaluating Patients With Impaired Hepatic Function
Completed·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 1·NCT00398424·24 enrolled
A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
Completed·VVectivBio AG·Phase 1·NCT05706623·16 enrolled
PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Completed·Novartis logoNovartis·Phase 1·NCT01429337·43 enrolled
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
Completed·CCassava Sciences, Inc.·Phase 1·NCT06390410·27 enrolled
A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function
Completed·Roche logoRoche·Phase 1·NCT06734208·31 enrolled
Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011
Completed·Novartis logoNovartis·Phase 1·NCT02388620·30 enrolled
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 1·NCT05391724·25 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)